Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study

Autor: Coates, L, Gladman, D, Nash, P, Fitzgerald, O, Kavanaugh, A, Kvien, T, Gossec, L, Strand, V, Rasouliyan, L, Pricop, L, Ding, K, Jugl, S, Gaillez, C, Group, Future 2 Study

Publikováno v: Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-11 (2018)
Arthritis Research & Therapy
Arthritis Research and Therapy
Arthritis Research and Therapy, BioMed Central, 2018, 20 (1), ⟨10.1186/s13075-018-1773-y⟩

Secukinumab has demonstrated sustained improvement in the signs and symptoms of psoriatic arthritis (PsA) over 2 years in the FUTURE 2 study (NCT01752634). This post hoc analysis assessed the ability of secukinumab to achieve Psoriatic Arthritis Dise

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e99e0847f08467d54f21cc1e36a45937
http://link.springer.com/article/10.1186/s13075-018-1773-y

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Secukinumab relieves anxiety/depression up to 1 year in patients treated for psoriatic arthritis and moderate to severe psoriasis: an overview from phase 3 clinical trials

Autor: Behrens, F, Mease, P, Lebwohl, M, Thaci, D, Gilloteau, I, Fox, T, DiComite, G, Guana, A, Jugl, S, Peterlik, D, Lefèvre, S, Gottlieb, AB

Publikováno v: 46. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 32. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), Wissenschaftliche Herbsttagung der Gesellschaft für Kinder-und Jugendrheumatologie (GKJR); 20180919-20180922; Mannheim; DOCSpA.21 /20190205/

Background: Psoriatic arthritis (PsA) and psoriasis patients are at greater risk for psychological distress, including depression and suicidality. Secukinumab is a fully human monoclonal antibody that selectively neutralizes IL-17A, a key cytokine in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7f3fe9040e8d6bab6156eab463d4141

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study.

Autor: Deodhar, A., Strand, V., Conaghan, P. G., Sullivan, E., Blackburn, S., Tian, H., Gandhi, K., Jugl, S. M., Alten, R.

Publikováno v: BMC Rheumatology; 3/2/2020, Vol. 4 Issue 1, p1-11, 11p